Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various bioph…
Biotechnology
US, New York [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 58.57 | 12.52 | 7.90 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 677.77 | -71.79 | 9.23 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -0.87 | 14.49 | 14.61 | |
| Cash | 75.25 | 1.94 | 1.11 | |
| Capex | 91.45 | -0.19 | -2.24 | |
| Free Cash Flow | 158.21 | 1.30 | -0.50 | |
| Revenue | -5.14 | 1.27 | 1.33 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -96.84 | -0.03 | 0.87 | |
| Operating Margin | -87.37 | -0.13 | 1.03 | |
| ROA | -99.02 | < 0.005 | 0.03 | |
| ROE | -99.03 | < 0.005 | 0.08 | |
| ROIC | -80.45 | < 0.005 | 0.03 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of RPRX is permitted for members.
5
Growth
The "Growth Entry" for the Focus of RPRX is permitted for members.
6
Leverage & Liquidity